NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 |
|
|
| Recruiting | 3 | 70 | US | RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control | ReGenTree, LLC | Neurotrophic Keratopathy | 07/24 | 11/24 | | |